Human immunodeficiency virus type-1 protease inhibitorstherapeutic successes and failures, suppression and resistance

Pharmacology and Therapeutics

Volumn 86, Issue 2, 2000, Pages 145-170

  Swanstrom, Ronald ^a,b   Erona, Joseph ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

HIV 1; Inhibitor; Protease; Resistance; Therapy

Indexed keywords

AMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG; VERTEX 478; VIRUS ENZYME; VIRUS PROTEIN; ZIDOVUDINE;

CLINICAL TRIAL; CROSS RESISTANCE; DISEASE COURSE; DRUG EFFICACY; DRUG RESISTANCE; DRUG TARGETING; ENZYME ACTIVE SITE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; VIRION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ANIMALS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS;

EID: 0034011309     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(00)00037-1     Document Type: Review

References (206)

1. Albrecht, M., Katzenstein, D., Bosch, R., Liou, S., & Hammer, S. (1998). ACTG 364: virologic efficacy of nelfinavir (NFV) and/or efavirenz (EFV) in combination with new nucleoside analogs in nucleoside experienced subjects. In Abstracts of the 12th World AIDS Conference (p. 52), Geneva, Switzerland, June 28. Stockholm: International AIDS Society.
2. Anonymous Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection. the CAESAR trial Lancet. 349:1997;1413-1421.
3. Ashorn P., McQuade T.J., Thaisrivongs S., Tomasselli A.G., Tarpley W.G., Moss B. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci USA. 87:1990;7272-7276.
4. Baldwin E.T., Bhat T.N., Liu B., Pattabiraman N., Erickson J.W. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. Nature Struct Biol. 2:1995;244-249.
5. Baldwin, J. R., Borin, M. T., Ferry, F. J., Hopkins, J. K., Azie, N. E., Williams, L. A., & Wang, Y. (1999). Pharmacokinetic (PK) interaction between the HIV protease inhibitors tipranavir and ritonavir. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (p. 23), San Francisco, CA, September 26-29. Washington, D.C.: American Society for Microbiology.
6. Baxter, J. D., Mayers, D. L., Wentworth, D. N., Neaton, J. D., Merigan, T. C., & the CPCRA 046 Study Team. (1999). Final results of CPCRA 046: a pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. In Abstracts of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies (p. 43), San Diego, CA, June 23-26. London: International Medical Press, Ltd.
7. Borin, M. T., Wang, Y., Schneck, D. W., Li, H., Brewer, J. E., & Daenzer, C. L. (1998). Multiple-dose, safety, tolerance, and pharmacokinetics of the protease inhibitor PNU-140690 in healthy volunteers. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infection (p. 201), Chicago, IL, February 1-5. Alexandria: Foundation for Retrovirology and Human Health.
8. Boucher, C., & Borleffs, J. (1998). Long-term evaluation of saquinavir-soft-gel-capsule or indinavir as part of combination triple therapy (CHEESE study). In Abstracts of the 12th World AIDS Conference (p. 65), Geneva, Switzerland, June 28. Stockholm: International AIDS Society.
9. Burger, D. M., Hugen, P. W. H., Prins, J. M., Van De Ende, M. E., Reiss, P., & Lange, J. M. A. (1999). Pharmacokinetics of an indinavir/ritonavir 800/100mg BID regimen. In Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (p. 136), Chicago, IL, January 31-February 4. Alexandria: Foundation for Retrovirology and Human Health.
10. Cameron D.W., Heath-Chiozzi M., Danner S., Cohen C., Kravcik S., Maurath C., Sun E., Henry D., Rode R., Potthoff A., Leonard J. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 351:1998;543-549.
11. Cameron D.W., Japour A.J., Xu Y., Hsu A., Mellors J., Farthing C., Cohen C., Poretz D., Markowitz M., Follansbee S., Angel J.B., McMahon D., Ho D., Devanarayan V., Rode R., Salgo M., Kempf D.J., Granneman R., Leonard J.M., Sun E. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS. 13:1999;213-224.
12. Carpenter C., Fischl M.A., Hammer S.M., Hirsch M.S., Jacobsen D.M., Katzenstein D.A., Montaner J., Richman D.D., Saag M.S., Schooley R.T., Thompson M.A., Vella S., Yeni P.G., Volberding P.A. Antiretroviral therapy for HIV infection in 1998. updated recommendations of the International AIDS Society-USA Panel JAMA. 280:1998;78-86.
13. Carrillo A., Stewart K.D., Sham H.L., Norbeck D.W., Kohlbrenner W.E., Leonard J.M., Kempf D.J., Molla A. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378. a novel protease inhibitor. J Virol. 72:1998;7532-7541.
14. Cassano, P., Hermans, P., Sommereijns, B., De Wit, S., Kabeya, K., O'Doherty, E., & Clumeck, N. (1998). Combined quadruple therapy with ritonavir-saquinavir (RTV-SQV) + nucleosides in patients who failed in triple therapy with RTV, SQV or indinavir (IDV). In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infection (p. 159), Chicago, IL, February 1-5. Alexandria: Foundation for Retrovirology and Human Health.
15. Guidelines for the use of antiretroviral therapy in HIV-infected adults and adolescents. MMWR. 47(No. RR-5):1998;43-65. a.
16. Report of the NIH panel to define principles of therapy of HIV infection. MMWR. 47(No. RR-5):1998;1-32. b.
17. Chen, C., Niu, P., Kati, W., Norbeck, D., Sham, H., Kempf, D., Kohlbrenner, W., Plattner, J., Leonard, J., & Molla, A. (1997). Activity of ABT-378 against HIV protease containing mutations conferring resistance to ritonavir. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infection (p. 103), Washington, D.C., January 22-26. Alexandria: Foundation for Retrovirology and Human Health.
18. Chen Z., Li Y., Schock H.B., Hall D., Chen E., Kuo L.C. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J Biol Chem. 270:1995;21433-21436.
19. Chong K.T., Pagano P.J. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob Agents Chemother. 41:1997;2367-2373.
20. Cohen, C., Mogyoros, M., Sands, M., Lentz, E., Siemon-Hryczyk, P., Pilson, R., & Duff, F. (1999). TIDBID Study: FORTOVASE™ (FTV) TID regimen compared to FTV BID or FTV + NFV BID regimens in HIV-1-infected patients. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (p. 472), San Francisco, CA, September 26-29. Washington, D.C.: American Society for Microbiology.
21. Condra J.H., Schleif W.A., Blahy O.M., Gabryelski L.J., Graham D.J., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Titus D., Yang T., Teppler H., Squires K.E., Deutsch P.J., Emini E.A. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 374:1995;569-571.
22. Condra J.H., Holder D.J., Schleif W.A., Blahy O.M., Danovich R.M., Gabryelski L.J., Graham D.J., Laird D., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Yang T., Chodakewitz J.A., Deutsch P.J., Leavitt R.Y., Massari F.E., Mellors J.W., Squires K.E., Steigbigel R.T., Teppler H., Emini E.A. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 70:1996;8270-8276.
23. Condra, J. H., Holder, D. J., Schleif, W. A., Bakshi, K., Danovich, R. M., Graham, D. J., Shivaprakash, M., Holmes, K., Saah, A. J., Leavitt, R. Y., Chodakewitz, J. A., & Emini, E. A. (1999). Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure. In Abstracts of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies (p. 44), San Diego, CA, June 23-26. London: International Medical Press, Ltd.
24. Craig J.C., Whittaker L., Duncan I.B., Roberts N.A. In vitro resistance to an inhibitor of HIV proteinase (Ro 31-8959) relative to inhibitors of reverse transcriptase (AZT and TIBO). Antiviral Chem Chemother. 4:1993;335-339.
25. Crawford S., Goff S.P. A deletion mutation in the 5′ part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the Gag and Pol polyproteins. J Virol. 53:1985;899-907.
26. Croteau G., Doyon L., Thibeault D., McKercher G., Pilote L., Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol. 71:1997;1089-1096.
27. Curry, R., Robinson, P., Hussain, S., Myers, M., & Robingson, P. (1998). Retained effectiveness of protease inhibitor (PI) therapy (Rx) following "protease sparing" nevirapine/nucleoside (NVP/nuc) combination therapy. In Abstracts of the 12th World AIDS Conference (p. 57), Geneva, Switzerland, June 28. Stockholm: International AIDS Society.
28. Danner S.A., Carr A., Leonard J.M., Lehman L.M., Gudiol F., Gonzales J., Raventos A., Rubio R., Bouza E., Pintado V., Aguado A.G., Garcia de Lomas J., Delgado R., Borleffs J.C.C., Hsu A., Valdes J.M., Boucher C.A.B., Cooper D.A. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 333:1995;1528-1533.
29. Darke P.L., Nutt R.F., Brady S.F., Garsky V.M., Ciccarone T.M., Leu C.T., Lumma P.K., Freidinger R.M., Veber D.F., Sigal I.S. HIV-1 protease specificity of peptide cleavage is sufficient for processing of Gag and Pol polyproteins. Biochem Biophys Res Commun. 156:1988;297-303.
30. Deeks S.G., Hellmann N.S., Grant R.M., Parkin N.T., Petropoulos C.J., Becker M., Symonds W., Chesney M., Volberding P.A. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen. antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome J Infect Dis. 179:1999;1375-1381.
31. Demeter, L., Hughes, M., Fischl, M., Grimes, J., Bosch, R., Squires, K., & Hammer, S. (1998). Predictors of virologic and clinical responses to indinavir (IDV) + ZDV + 3TC or ZDV + 3TC. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infection (p. 175), Chicago, IL, February 1-5. Alexandria: Foundation for Retrovirology and Human Health.
32. De Pasquale, M. P., Murphy, R., Kuritzkes, D., Martinez-Picado, J., Sommadossi, J.-P., Gulick, R., Smeaton, L., DeGruttola, V., Caliendo, A., Sutton, L., Savara, A. V., & D'Aquila, R. T. (1998). Mutations selected in HIV plasma RNA during 141W94 therapy. In Abstracts of the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies (p. 50), Lake Maggiore, Italy, June 24-27. London: International Medical Press, Ltd.
33. de Truchis, P., Force, G., Zucman, D., Leclerc, V., Rouveix, E., Simonpoli, A. M., & Berthe, H. (1998). Effects of a "salvage" combination therapy with ritonavir + saquinavir in HIV-infected patients previously treated with protease-inhibitors (PI). In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infection (p. 159), Chicago, IL, February 1-5. Alexandria: Foundation for Retrovirology and Human Health.
34. Dianzani F., Antonelli G., Turriziani O., Riva E., Dong G., Bellarosa D. In vitro selection of human immunodeficiency virus type 1 resistant to Ro 31-8959 proteinase inhibitor. Antiviral Chem Chemother. 4:1993;329-333.
35. Dittmar K.J., Moelling K. Biochemical properties of p15-associated protease in an avian RNA tumor virus. J Virol. 28:1978;106-118.
36. Doyon L., Croteau G., Thibeault D., Poulin F., Pilote L., Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol. 70:1996;3763-3769.
37. Dulioust A., Paulous S., Guillemot L., Delavalle A.M., Boue F., Clavel F. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. J Virol. 73:1999;850-854.
38. Durant J., Clevenbergh P., Halfon P., Delgiudice P., Porsin S., Simonet P., Montagne N., Boucher C.A., Schapiro J.M., Dellamonica P. Drug-resistance genotyping in HIV-1 therapy. the VIRADAPT randomised controlled trial Lancet. 353:1999;2195-2199.
39. Eastman P.S., Mittler J., Kelso R., Gee C., Boyer E., Kolberg J., Urdea M., Leonard J.M., Norbeck D.W., Hongmei M., Markowitz M. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol. 72:1998;5154-5164.
40. Eberle J., Bechowsky B., Rose D., Hauser U., Von Der Helm K., Gurtler L., Nitschko H. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res Hum Retroviruses. 11:1995;671-676.
41. El-Farrash M.A., Kuroda M.J., Kitazaki T., Masuda T., Kato K., Hatanaka M., Harada S. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol. 68:1994;233-239.
42. Erickson J., Neidhart D.J., VanDrie J., Kempf D.J., Wang X.C., Norbeck D.W., Plattner J.J., Rittenhouse J.W., Turon M., Wideburg N., Kohlbrenner W.E., Simmer R., Hlefrich R., Paul D.A., Knigge M. Design, activity, and 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science. 249:1990;527-533.
43. Erickson-Viitanen S., Manfredi J., Viitanen P., Tribe D.E., Tritch R., Hutchison C.A.I., Loeb D.D., Swanstrom R. Cleavage of HIV-1 gag polyprotein synthesized in vitro. sequential cleavage by the viral protease AIDS Res Hum Retroviruses. 5:1989;577-591.
44. Ermolieff J., Lin X., Tang J. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. Biochemistry. 36:1997;12364-12370.
45. Eron J.J., Benoit S.L., Jemsek J., MacArthur R.D., Santana J., Quinn J.B., Kuritzkes D.R., Fallon M.A., Rubin M. Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200-500 CD4+ cells per cubic millimeter. N Engl J Med. 333:1995;1662-1669.
46. Eron, J., Haubrich, R., Richman, D., Lang, W., Tisdale, M., Myers, R., Pagano, G., & Rogers, M. (1998a). Preliminary assessment of 141W94 in combination with other protease inhibitors. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infection (p. 80), Chicago, IL, February 1-5. Alexandria: Foundation for Retrovirology and Human Health.
47. Eron, J., Peterson, D., Murphy, R., Jemsek, J., Pottage, J., Parenti, D., Esinhart, J., Schoellkopf, N., & Stevens, M. (1998b). An open-label, randomized, comparative study of d4T + ddI + IDV versus ZDV + 3TC + IDV in treatment naive HIV infected patients. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infection (p. 150), Chicago, IL, February 1-5. Alexandria: Foundation for Retrovirology and Human Health.
48. Eron, J., King, M., Xu, Y.,Brun, S., Real, K., Murphy, R., Gulick, R., Glesby, M., Hicks, C., Benson, C., Thompson, M., Thommes, J., Kessler, H., Deeks, S., Wheeler, D., White, M., Stryker, R., Feinberg, J., Albrecht, M., Pax, P., Riddler, S., Hsu, A., Bertz, R., Molla, A., Mo, H., Kempf, D., Japour, A., & Sun, E. (1999). ABT-378/ritonavir (ABT-387/r) suppresses HIV RNA to >400 copies/mL in 95% of treatment-naïve patients and in 78% of PI-experienced patients at 36 weeks. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (p. 18), San Francisco, CA, September 26-29. Washington, D.C.: American Society for Microbiology.
49. Eyster, E., Jemsek, J., Kagan, S., Martin, G., Seekins, D., Steigbigel, R., & Manion, D. J. (1998). Initial effectiveness and tolerability of nelfinavir (NFV) in combination with efavirenz (EFV, SUSTIVA, DMP 266) in antiretroviral therapy naive or nucleoside analogue experienced HIV-1 infected patients: characterization in a phase II, open-label, multicenter study at 24 weeks (Study DMP 266-024). In Abstracts of the 12th World AIDS Conference (p. 341), Geneva, Switzerland, June 28. Stockholm: International AIDS Society.
50. Farthing, C., Mess, T., Ried, C., Radhakrishna, S., & Wallace, M. (1998). Ritonavir, saquinavir, and nevirapine as a salvage regimen for indinavir or ritonavir resistance. In Abstracts of the 12th World AIDS Conference (p. 335), Geneva, Switzerland, June 28. Stockholm: International AIDS Society.
51. Faye, A., Race, E., Obry, V., Prevot, M. H., Joly, V., Matheron, S., Damond, F., Dam, E., Paulous, S., & Clavel, F. (1999). Can resistance-associated loss of viral fitness explain discordant CD4 and plasma HIV RNA evolution following protease inhibitor failure? In Abstracts of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies (p. 91), San Diego, CA, June 23-26. London: International Medical Press, Ltd.
52. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1997;1295-1300.
53. Fischl M.A., Richman D.D., Flexner C., Para M.F., Haubrich R., Karim A., Yeramian P., Holden-Wiltse J., Meehan P.M. Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. J Acquir Immune Defic Syndr. 15:1997;28-34.
54. Flexner C. HIV-protease inhibitors. N Engl J Med. 338:1998;1281-1292.
55. Flexner, C., Hsu, A., Kerr, B., Wong, C., Gallant, J., Anderson, R., & Health-Chiozzi, M. (1998). Steady-state pharmacokinetic interactions between ritonavir (RTV), nelfinavir (NFV), and the nelfinavir active metabolite M8 (AG1402). In Abstracts of the 12th World AIDS Conference (p. 826), Geneva, Switzerland, June 28. Stockholm: International AIDS Society.
56. Fu W., Rein A. Maturation of dimeric viral RNA of Moloney murine leukemia virus. J Virol. 67:1993;5443-5449.
57. Fu W., Gorelick R.J., Rein A. Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and protease-defective virions. J Virol. 68:1994;5013-5018.
58. Gallant, J., Health-Chiozzi, M., Anderson, R., Fields, C., & Flexner, C. (1998). Phase II study of ritonavir-nelfinavir combination therapy: an update. In Abstracts of the 12th World AIDS Conference (pp. 52-53), Geneva, Switzerland, June 28. Stockholm: International AIDS Society.
59. Gange, S. J., Mellors, J. W., Schrager, L., Margolick, J. B., Giorgi, J. V., Detels, R., Phair, J., & Munoz, A. (1998). Longitudinal plasma HIV RNA patterns among HIV-1 infected individuals with late disease progression. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infection (p. 12), Chicago, IL, February 1-5. Alexandria: Foundation for Retrovirology and Human Health.
60. Gitti R.K., Lee B.M., Walker J., Summers M.F., Yoo S., Sundquist W.I. Structure of the amino-terminal core domain of the HIV-1 capsid protein. Science. 273:1996;231-235.
61. Gong, Y., Robinson, B., Rose, R., Riccardi, K., Deminie, C., Stock, D., Spicer, T., Djang, F., Cross, J., Colonno, R., & Lin, P.-F. (1999). Resistance profile and drug combination studies of an HIV-1 protease inhibitor BMS-232632. In Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (p. 181), Chicago, IL, January 31-February 4. Alexandria: Foundation for Retrovirology and Human Health.
62. Gottlinger H.G., Sodroski J.G., Haseltine W.A. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 86:1989;5781-5785.
63. Gowda S.D., Stein B.S., Engleman E.G. Identification of protein intermediates in the processing of the p55 HIV-1 gag precursor in cells infected with recombinant vaccinia virus. J Biol Chem. 264:1989;8459-8462.
64. Gross I., Hohenberg H., Huckhagel C., Krausslich H.-G. N-terminal extensions of human immunodeficiency virus capsid protein convert the in vitro assembly phenotype from tubular to spherical particles. J Virol. 72:1998;4798-4810.
65. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Richman D.D., Valentine F.T., Jonas L., Deutsch P., Meibohm A., Holder D., Schleif W.A., Condra J.H., Emini E.A., Chodakewitz J.A. Treatment with a combination of indinavir, zidovudine and lamivudine in HIV-1 infected adults with prior antiretroviral use. N Engl J Med. 337:1997;734-739.
66. Gulick R., Mellors J., Havlir D., Eron J., Gonzalez C., McMahon D., Jonas L., Meibohm A., Holder R.D., Schleif W.A., Condra J.H., Emini E.A., Isaacs R., Chodakewitz J.A., Richman D.D. Simultaneous vs. sequential initiation of therapy with indinair, zidovudine, and lamivudine for HIV-1 infection. 100 week follow-up JAMA. 280:1998;35-41.
67. Gulick, R. M., Katzenstein, D., Hu, J., Fiscus, F. A., Fletcher, C. V., Haubrich, R., Cheng, H., Acosta, E., Lagakos, S., Swanstrom, R., Parkin, N., Snyder, S., Mills, C., Fischl, M., Pettinelli, C. for the ACTG 359 Protocol Team. (1999a). Salvage therapy with saquinavir soft gel capsules in combination with ritonavir or nelfinavir and delavirdine, adefovir dipivoxil, or both: ACTG 359. In Program & Abstracts of the Second International Workshop on Salvage Therapy for HIV Infection (p. 19), Toronto, May 19-21. London: International Medical Press, Ltd.
68. Gulick, R., Mellors, J., Havlir, D., Eron, J., Valentine, F., McMahon, D., Gonzalez, C., Jonas, L., Meibohm, A., Chodakewitz, J., Isaacs, R., & Richman, D. (1999b). Treatment with indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC): three-year follow-up. In Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (p. 140), Chicago, IL, January 31-February 4. Alexandria: Foundation for Retrovirology and Human Health.
69. Gulnik S.V., Suvorov L.I., Liu B., Yu B., Anderson B., Mitsuya H., Erickson J.W. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry. 34:1995;9282-9287.
70. Hall C.S., Raines C.P., Barnett S.H., Moore R.D., Gallant J.E. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. AIDS. 13:1999;1207-1212.
71. Hammer S., Katzenstein D., Hughes M., Gundacker H., Schooley R., Haubrich R., Henry W., Lederman M., Phair J., Niu M., Hirsch M., Merigan T. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 335:1996;1081-1090.
72. Hammer S.M., Squires K., Hughes M., Grimes J., Demeter L., Courier J., Eron J.J., Feinberg J., Balfour H., Deyton L., Chodakewitz J., Fischl M., Nguyen B.-Y., Spreen W., Pedneault L., Kuritzkes D. A randomized, placebo-controlled trial of indinavir in combination with two nucleoside analogs in human immunodeficiency virus infected persons with CD4 cell counts less than or equal to 200 per cubic millimeter. N Engl J Med. 337:1997;725-733.
73. Hammer, S., Demeter, L., DeGruttola, V., Bassett, R., Mellors, J., Squires, K., Fischl, M., Hertogs, K., Larder, B., & the ACTG 372 Study Team (1999). Relationship of phenotypic and genotypic resistance profiles to virological outcome in a trial of abacavir, nelfinavir, efavirenz and adefovir dipivoxil in patients with virological failure receiving indinavir (ACTG 372). In Abstracts of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies (p. 45), San Diego, CA, June 23-26. London: International Medical Press, Ltd.
74. Harrigan, P., Montaner, J., Hogg, R., Yip, B., Hertogs, K., Pauwels, R., Bloor, S., & Larder, B. (1998). Baseline resistance profile predicts response to ritonavir/saquinavir therapy in a community setting. In Abstracts of the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies (p. 38), Lake Maggiore, Italy, June 24-27. London: International Medical Press, Ltd.
75. Harris, M., Durakovic, C., Conway, B., Fransen, S., Shillington, A., & Montaner, J. S. (1997). A pilot study of indinavir, nevirapine, and 3TC in patients with advanced HIV disease. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infection (p. 107), Washington, D.C., January 22-26. Alexandria: Foundation for Retrovirology and Human Health.
76. Henderson L.E., Benveniste R.E., Sowder R., Copeland T.D., Schultz A.M., Oroszlan S. Molecular characterization of Gag proteins from simian immunodeficiency virus (SIVMne). J Virol. 62:1988;2587-2595.
77. Hertogs K., de Bethune M.P., Miller V., Ivens T., Schel P., Van Cauwenberge A., Van Den Eynde C., Van Gerwen V., Azijn H., Van Houtte M., Peeters F., Staszewski S., Conant M., Bloor S., Kemp S., Larder B., Pauwels R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother. 42:1998;269-276.
78. Hicks, C. B., Lehman, L., Eron, J., Horton, J., Jemsek, J., Kelly, N., & Leonard, J. (1996). Safety and efficacy of ritonavir administered at two potentially maximum tolerated doses. In Abstracts of the 11th International Conference on AIDS (p. 25), Vancouver, July 7-12. Stockholm: Internal AIDS Society.
79. Hirsch, M., Meibohm, A., Rawlins, S., & Leavitt, R. (1997). Indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC) in ZDV-experienced patients with CD4 cell counts less than or equal to 50 cells/mm(3). In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infection (p. 207), Washington, D.C., January 22-26. Alexandria: Foundation for Retrovirology and Human Health.
80. Ho D.D., Toyoshima T., Mo H., Kempf D.J., Norbeck D., Chen C.M., Wideburg N.E., Burt S.K., Erickson J.W., Singh M.K. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol. 68:1994;2016-2020.
81. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:1995;123-126.
82. Hsu, A., Granneman, R., Heath-Chiozzi, M., Wong, C., Manning, L., Brooks, T., & Sun, E. (1998). Indinavir can be taken with regular meals when administered with ritonavir. In Abstracts of the 12th World AIDS Conference (p. 336), Geneva, Switzerland, June 28. Stockholm: International AIDS Society.
83. Ives K.J., Jacobsen H., Galpin S.A., Garaev M.M., Dorrell L., Mous J., Bragman K., Weber J.N. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J Antimicrob Chemother. 39:1997;771-779.
84. Jacks T. Translational suppression in gene expression in retroviruses and retranspoons. Curr Top Microbiol Immunol. 157:1990;93-124.
85. Jacobsen H., Yasargil K., Winslow D.W., Craig C., Krohn A., Duncan I.B., Mous J. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology. 206:1995;527-534.
86. Jacobsen H., Hanggi M., Ott M., Duncan I.B., Owen S., Andreoni M., Vella S., Mous J. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor. mutations, kinetics, and frequencies J Infect Dis. 173:1996;1379-1387.
87. Japour, A., Murphy, R., Hicks, C., Eron, J., Yetzer, E., Hammer, S., & Orth, K. (1998). Safety and efficacy of ABT-378/ritonavir in antiretroviral naive patients: preliminary phase II results. In Abstracts of the 12th World AIDS Conference, Geneva, Switzerland, June 28. Stockholm, International AIDS Society.
88. Kaplan A.H., Zack J.A., Knigge M., Paul D.A., Kempf D.J., Norbeck D.W., Swanstrom R. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol. 67:1993;4050-4055.
89. Kaplan A.H., Krogstad P., Kempf D.J., Norbeck D.W., Swanstrom R. Human immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of reverse transcribing viral genomic RNA. Antimicrob Agents Chemother. 38:1994;2929-2933. a.
90. Kaplan A.H., Michael S.F., Wehbie R.S., Knigge M.F., Paul D.A., Everitt L., Kempf D.J., Norbeck D.W., Erickson J.W., Swanstrom R. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci USA. 91:1994;5597-5601. b.
91. Katoh I., Yoshinaka Y., Rein A., Shibuya M., Odaka T., Oroszlan S. Murine leukemia virus maturation. protease region required for conversion from "immature" to "mature" core form and for virus infectivity Virology. 145:1985;280-292.
92. Katoh I., Yasunaga T., Ikawa Y., Yoshinaka Y. Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor. Nature. 329:1987;654-656.
93. Katzenstein D., Hammer S., Hughes M., Gundacker H., Jackson J., Fiscus S., Rasheed S., Elbeik T., Reichman R., Japour A. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med. 335:1996;1091-1098.
94. Kempf D.J., Marsh K.C., Denissen J.F., McDonald E., Vasavanonda S., Flentge C.A., Green B.E., Fino L., Park C.H., Kong X.P., Wideburg N.E., Saldivar A., Ruiz L., Kati W.M., Sham H.L., Robins T., Stewart K.D., Hsu A., Plattner J.J., Leonard J.M., Norbeck D.W. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA. 92:1995;2484-2488.
95. Kempf, D., Marsh, K., Denissen, J., Kumar, G., Rodrigues, D., McDonald, E., Flentge, C., Green, B., Chen, X., Leonard, J., & Norbeck, D. (1996). Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infection (p. 79), Washington, D.C., January 28-February 1. Arlington: Infectious Disease Society of America.
96. Kitchen V.S., Skinner C., Ariyoshi K., Lane E.A., Duncan I.B., Burckhardt J., Burger H.U., Bragman K., Pinching A.J., Weber J.N. Safety and activity of saquinavir in HIV infection. Lancet. 345:1995;952-955.
97. Klabe R., Bacheler L., Ala P., Erickson-Viitanen S., Meek J. Resistance to HIV protease inhibitors. a comparison of enzyme inhibition and antiviral potency Biochemistry. 37:1998;8735-8742.
98. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimbach J.C., Dixon R.A., Scolnick E.M., Sigal I.S. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA. 85:1988;4686-4690.
99. Konvalinka J., Litterst M.A., Welker R., Kottler H., Rippmann F., Heuser A.M., Krausslich H.G. An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity. J Virol. 69:1995;7180-7186.
100. Korneyeva, M., Chernyvskiy, T., Norbeck, D., Sham, H., Kempf, D., Kohlbrenner, W., Plattner, J., Leonard, J., & Molla, A. (1997). Virological evaluation of ritonavir-resistant HIV to the HIV protease inhibitor ABT-378. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infection (p. 103), Washington, D.C., January 22-26. Alexandria: Foundation for Retrovirology and Human Health.
101. Krausslich H.-G., Schneider H., Zybarth G., Carter C.A., Wimmer E. Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli. J Virol. 62:1988;4393-4397.
102. Kumar, G. N., Jayanti, V., Johnson, M. K., & Denissen, J. F. (1997). Increased bioavailability and plasma levels of the HIV-1 protease inhibitor ABT-378 in rats due to inhibition of the in vivo metabolism by ritonavir. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infection (p. 103), Washington, D.C., January 22-26. Alexandria: Foundation for Retrovirology and Human Health.
103. Lal, R., Hsu, A., Granneman, G. R., El-Shourbagy, T., Johnson, M., Lam, W., Manning, L., Japour, A., & Sun, E. (1998). Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infection (p. 201), Chicago, IL, February 1-5. Alexandria: Foundation for Retrovirology and Human Health.
104. Lapatto R., Blundell T., Hemmings A., Overington J., Wilderspin A., Wood S., Merson J.R., Whittle P.J., Danley D.E., Geoghegan K.F., Hawrylik S.J., Lee S.E., Scheld K.G., Hobart P.M. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes. Nature. 342:1989;299-302.
105. Larder, B. A., Bloor, S., Hertogs, K., Van Den Eynde, C., DeCian, W., Wang, Y., & Freimuth, W. (1999) Tipranavir is active against a large selection of highly protease inhibitor resistant HIV-1 clinical samples. In Abstracts of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies (p. 5), San Diego, CA, June 23-26. London: International Medical Press, Ltd.
106. Lazdins J.K., Mestan J., Goutte G., Walker M.R., Bold G., Capraro H.G., Klimkait T. In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755. a comparative study with other relevant HIV protease inhibitors J Infect Dis. 175:1997;1063-1070.
107. Lillehoj E.P., Salazar F.H., Mervis R.J., Raum M.G., Chan H.W., Ahmad N., Venkatesan S. Purification and structural characterization of the putative Gag-Pol protease of human immunodeficiency virus. J Virol. 62:1988;3053-3058.
108. Livington D.J., Pazhanisamy S., Porter D.J., Partaledis J.A., Tung R.D., Painter G.R. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis. 172:1995;1238-1245.
109. Lorenzi P., Opravil M., Hirschel B., Chave J.P., Furrer H.J., Sax H., Perneger T.V., Perrin L., Kaiser L., Yerly S. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS. 13:1999;F17-F21.
110. Maguire, M. F., Klein, A. P., Snowden, B. W., & Tisdale, M. (1999). Development of linked V32I and I47V HIV-1 protease substitutions in some NRTI-experienced amprenavir-treated subjects. In Abstracts of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies (p. 29), San Diego, CA, June 23-26. London: International Medical Press, Ltd.
111. Mahalingam B., Louis J.M., Reed C.C., Adomat J.M., Krouse J., Wang Y.F., Harrison R.W., Weber I.T. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur J Biochem. 263:1999;238-245.
112. Mammano F., Petit C., Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1. phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients J Virol. 72:1998;7632-7637.
113. Markowitz M., Mo H., Kempf D.J., Norbeck D.W., Bhat T.N., Erickson J.W., Ho D.D. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol. 69:1995;701-706. a.
114. Markowitz M., Saag M., Powderly W.G., Hurley A.M., Hsu A., Valdes J.M., Henry D., Sattler F., La Marca A., Leonard J.M., Ho D.D. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 333:1995;1534-1539. b.
115. Markowitz M., Conant M., Hurley A., Schluger R., Duran M., Peterkin J., Chapman S., Patick A., Hendrick A., Yuen G.J., Hoskins W., Clendeninn N., Ho D.D. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis. 177:1998;1533-1540.
116. Martinez-Picado J., Savara A.V., Sutton L., D'Aquila R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol. 73:1999;3744-3752.
117. Maschera B., Furfine E., Blair E.D. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol. 69:1995;5431-5436.
118. Maschera B., Darby G., Palu G., Wright L.L., Tisdale M., Myers R., Blair E.D., Furfine E.S. Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J Biol Chem. 271:1996;33231-33235.
119. Massari, F., Staszewski, S., Berry, P., Kahn, J., Frank, I., Heathchiozzi, M., Sampson, J., Eron, J., Eyster, E., Teppler, H., Schleif, W., Condra, J., Leavitt, R., & Emini, E. (1995). A double-blind, randomized trial of indinavir (MK-639) alone or with zidovudine vs zidovudine alone in zidovudine naive patients. In 35th ICAAC (p. 9), San Francisco, September 17-20. Washington, D.C.: American Society of Microbiology.
120. Massari, F., Conant, M., Mellors, J., Steigbigel, R., Mildvan, D., Greenberg, R., Carpenter, C., Murphy, R., Squires, K., Rigsby, M., Drusano, G., McKinley, G., Gilde, L., & Nessly, M. (1996). A phase II open-label, randomized study of the triple combination of indinavir, zidovudine (ZDV) and didanosine (DDI) versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infection (p. 90), Washington, D.C., January 28-February 1. Arlington: Infectious Disease Society of America.
121. Mayers, D. L., Neaton, J. D., Perez, G., Baxter, J. D., MacArthur, R. D., Markowitz, N. P., Dehlinger, M. E., Howard, S. F., & Thompson, M. A. (1998). Prior saquinavir therapy leads to a modest decrease in subsequent responses to drug regimens containing indinavir or ritonavir. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infection (p. 154), Chicago, IL, February 1-5. Alexandria: Foundation for Retrovirology and Human Health.
122. Meek T.D., Lambert D.M., Dreyer G.B., Carr T.J., Tomaszek T.A.J., Moore M.L., Strickler J.E., Debouck C., Hyland L.J., Matthews T.J., Metcalf B.W., Petteway S.R. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature. 343:1990;90-92.
123. Mellors J.W., Kingsley L.A., Rinaldo C.R. Jr., Todd J.A., Hoo B.S., Kokka R.P., Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 122:1995;573-579.
124. Mellors J., Rinaldo C., Gupta P., White R., Todd J., Kingsley L. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1996;1167-1170.
125. Mellors J.W., Munoz A., Giorgi J.V., Margolick J.B., Tassoni C.J., Gupta P., Kingsley L.A., Todd J.A., Saah A.J., Detels R., Phair J.P., Rinaldo C.R. Jr. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 126:1997;946-954.
126. Merry C., Barry M.G., Mulcahy F., Halifax K.L., Back D.J. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS. 11:1997;F117-F120.
127. Mervis R.J., Ahmad N., Lillehoj E.P., Raum M.G., Salazar F.H., Chan H.W., Venkatesan S. The gag gene products of human immunodeficiency virus type 1. alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative Gag precursors J Virol. 62:1988;3993-4002.
128. Miller M., Schneider J., Sathyanarayana B.K., Toth M.V., Marshall G.R., Clawson L., Selk L., Kent S.B., Wlodawer A. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Å resolution. Science. 246:1989;1149-1152.
129. Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P.J., Mo H.-M., Markowitz M., Chernyavskiy T., Niu P., Lyons N., Hsu A., Granneman R., Ho D.D., Boucher C.A.B., Leonard J.M., Norbeck D.W., Kempf D.J. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 2:1996;760-766.
130. Molla, A., Vasavanonda, S., Denissen, J., Kumar, G., Grabowski, B., Sham, H., Norbeck, D., Kohlbrenner, W., Plattner, J., Kempf, D., & Leonard, J. (1997). Effect of human serum proteins on the antiretroviral activity of ritonavir and ABT-378, potent inhibitors of HIV protease. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infection (p. 104), Washington, D.C., January 22-27. Alexandria: Foundation for Retrovirology and Human Health.
131. Molla A., Vasavanonda S., Kumar G., Sham H.L., Johnson M., Grabowski B., Denissen J.F., Kohlbrenner W., Plattner J.J., Leonard J.M., Norbeck D.W., Kempf D.J. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology. 250:1998;255-262.
132. Moore M.L., Bryan W.M., Fakhoury S.A., Magaard V.W., Huffman W.F., Dayton B.D., Meek T.D., Hyland L., Dreyer G.B., Metcalf B.W., Strickler J.E., Gorniak J.G., Debouck C. Peptide substrates and inhibitors of the HIV-1 protease. Biochem Biophys Res Commun. 159:1989;420-425.
133. Moyle, G. (1998). Study of protease inhibitor combination in Europe (SPICE): saquinavir soft gelatin capsule (SQV-SGC) plus nelfinavir (NFV) in HIV-infected individuals. In Abstracts of the 12th World AIDS Conference (p. 56), Geneva, Switzerland, June 28. Stockholm: International AIDS Society.
134. Murphy R.L., Gulick R.M., DeGruttola V., D'Aquila R.T., Eron J.J., Sommadossi J.P., Currier J.S., Smeaton L., Frank I., Caliendo A.M., Gerber J.G., Tung R., Kuritzkes D.R. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis. 179:1999;808-816.
135. Navia M.A., Fitzgerald P.M., McKeever B.M., Leu C.T., Heimbach J.C., Herber W.K., Sigal I.S., Darke P.L., Springer J.P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature. 337:1989;615-620.
136. Olsen D.B., Stahlhut M.W., Rutkowski C.A., Schock H.B., vanOlden A.L., Kuo L.C. Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors. J Biol Chem. 274:1999;23699-23701.
137. Oroszlan S., Luftig R.B. Retroviral proteinases. Curr Top Microbiol Immunol. 157:1990;153-185.
138. Otto M.J., Garber S., Winslow D.W., Reid C.D., Aldrich P., Jadhav P.K., Patterson C.E., Hodge C.N., Cheng Y.-S.E. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci USA. 90:1993;7543-7547.
139. Painter, G. R., St Clair, M. H., Demiranda, P., Reynolds, D., Ching, S., Dornsife, R., Livingston, D. J., Pazhanisamy, S., & Tung, R. (1995). An overview of the preclinical development of the HIV protease inhibitor VX-478 (141W94). In Abstracts of the 2nd National Conference on Human Retroviruses Related Infection (abstract 167), Washington, D.C., January 29-February 2. Arlington: Infectious Disease Society of America.
140. Palella F.J. Jr., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 338:1998;853-860.
141. Para, M., & Weinstock, M. (1998). Retrospective analysis of protease inhibitor efficacy among patients failing a delavirdine regimen. In Abstracts of the 12th World AIDS Conference (p. 59), Geneva, Switzerland, June 28. Stockholm: International AIDS Society.
142. Para, M. F., Coombs, R., Collier, A., Glidden, D., Bassett, R., Duff, F., Boucher, C., Leavitt, R. Y., Condra, J., & Pettinelli, C. (1998). Relationship of baseline genotype to RNA response in ACTG 333 after switching from long term saquinavir (SQVhc) to indinavir (IDV) or saquinavir soft gelatin capsule (SQVsgc). In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infection (p. 175), Chicago, IL, February 1-5. Alexandria: Foundation for Retrovirology and Human Health.
143. Parkin N.T., Lie Y.S., Hellmann N., Markowitz M., Bonhoeffer S., Ho D.D., Petropoulos C.J. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. J Infect Dis. 180:1999;865-870.
144. Partaledis J.A., Yamaguchi K., Tisdale M., Blair E.E., Falcione C., Maschera B., Myers R.E., Pazhanisamy S., Futer O., Cullinan A.B., Stuver C.M., Byrn R.A., Livingston D.J. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol. 69:1995;5228-5235.
145. Patick A.K., Mo H., Markowitz M., Appelt K., Wu B., Musick L., Kalish V., Kaldor S., Reich S., Ho D., Webber S. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother. 40:1996;292-297.
146. Patick A.K., Duran M., Cao Y., Shugarts D., Keller M.R., Mazabel E., Knowles M., Chapman S., Kuritzkes D.R., Markowitz M. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother. 42:1998;2637-2644.
147. Patick, A. K., Shintani, M., Sato, H., Ueno, T., Mimoto, T., Hayashi, H., Nash, T. C., Wang, B., Jackson, R. L., Cao, J. Q., & Potts, K. E. (1999). Antiviral activity and resistance profile of AG1776, a novel inhibitor of HIV-1 protease. In Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (p. 69), Chicago, IL, January 31-February 4. Alexandria: Foundation for Retrovirology and Human Health.
148. Pazhanisamy S., Partaledis J.A., Rao B.G., Livingston D.J. In vitro selection and characterization of VX-478 resistant HIV-1 variants. Adv Exp Med Biol. 436:1998;75-83.
149. Pearl L.H., Taylor W.R. A structural model for the retroviral proteases. Nature. 329:1987;351-354.
150. Pedersen, C., Gerstoft, J., Lunnogren, J., Mathiesen, L., Kirk, O., Nielsen, H., & Katzenstein, T. (1998). Saquinavir/ritonavir may have better antiviral efficacy than either ritonavir or indinavir in HIV infected antiRetroviral naive patients. In Abstracts of the 12th World AIDS Conference (p. 55), Geneva, Switzerland, June 28. Stockholm: International AIDS Society.
151. Perelson A., Neumann A., Markowitz M., Leonard J., Ho D. HIV-1 dynamic in vivo. virion clearance rate, infected cell life-span and viral generation time Science. 271:1996;1582-1586.
152. Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin M.T., Huang W., Tian H., Smith D., Winslow G.A., Capon D., Whitcomb J. A novel phenotypic drug susceptibility assay for HIV-1. Antimicrob Agents Chemother. in press:2000.
153. Pettit S.C., Simsic J., Loeb D.D., Everitt L., Hutchison C.A. III, Swanstrom R. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. J Biol Chem. 266:1991;14539-14547.
154. Pettit S.C., Michael S.F., Swanstrom R. The specificity of the HIV-1 protease. Perspect Drug Disc Des. 1:1993;69-83.
155. Piketty C., Race E., Castiel P., Belec L., Peytavin G., Si-Mohamed A., Gonzalez-Canali G., Weiss L., Clavel F., Kazatchkine M.D. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen. phenotypic resistance to protease inhibitors predicts outcome of therapy AIDS. 13:1999;F71-F77.
156. Poppe S.M., Slade D.E., Chong K.T., Hinshaw R.R., Pagano P.J., Markowitz M., Ho D.D., Mo H., Gorman R.R. III, Dueweke T.J., Thaisrivongs S., Tarpley W.G. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother. 41:1997;1058-1063.
157. Richards A.D., Roberts R., Dunn B.M., Graves M.C., Kay J. Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases. FEBS Lett. 247:1989;113-117.
158. Riddler, S., Kahn, J., Hicks, C., Havlir, D., Stein, D., Horton, J., & Ruiz, N. (1998). Durable clinical anti-HIV-1 activity (72 weeks) and tolerability for efavirenz (DMP 266) in combination with indinavir (IDV) [DMP 266-003, Cohort IV]. In Abstracts of the 12th World AIDS Conference (p. 85), Geneva, Switzerland, June 28. Stockholm: International AIDS Society.
159. Ridky T.W., Kikonyogo A., Leis J., Gulnik S., Copeland T., Erickson J., Wlodawer A., Kurinov I., Harrison R.W., Weber I.T. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. Biochemistry. 37:1998;13835-13845.
160. Roberts N.A., Martin J.A., Kinchington D., Broadhurst A.V., Craig J.C., Duncan I.B., Galpin S.A., Handa B.K., Kay J., Krohn A., Lambert R.W., Merrett J.H., Mills J.S., Parkes K.E.B., Redshaw S., Ritchie A.J., Taylor D.L., Thomas G.J., Machin P.J. Rational design of peptide-based HIV proteinase inhibitors. Science. 248:1990;358-361.
161. Robey W.G., Safai B., Oroszlan S., Arthur L.O., Gonda M.A., Gallo R.C., Fischinger P.J. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science. 228:1985;593-595.
162. Rose J.R., Babe L.M., Craik C.S. Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J Virol. 69:1995;2751-2758.
163. Rose R.B., Craik C.S., Stroud R.M. Domain flexibility in retroviral proteases. structural implications for drug resistant mutations Biochemistry. 37:1998;2607-2621.
164. Rose R.E., Gong Y.-F., Greytok J.A., Bechtold C.M., Terry B.J., Robinson B.S., Alam M., Colonno R.J., Lin P.-F. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci USA. 93:1996;1648-1653.
165. Saag, M., Knowles, M., Chang, Y., Chapman, S., Clendeninn, N., & for the VIRACEPT Cooperative Study Group (1997). Durable effect of VIRACEPT (nelfinavir mesylate, NFV) in triple combination therapy. In 37th ICAAC (p. 261), Toronto, Canada, September 28-October 1. Washington, D.C.: American Society of Microbiology.
166. Saah, A., Riddler, S., Havlir, D., Squires, K., Anderson, R., Kerr, S., Yeh, K., & Deutsch, P. (1998). Co-administration of indinavir and nelfinavir: pharmacokinetics, tolerability, anti-viral activity, and preliminary viral resistance. In Abstracts of the 12th World AIDS Conference (p. 334), Geneva, Switzerland, June 28. Stockholm, International AIDS Society.
167. Saah, A. J., Winchell, G., Seniuk, M., & Deutsch, P. (1999). Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) ritonavir (RTV) combinations in healthy volunteers. In Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (p. 136), Chicago, IL, January 31-February 4. Alexandria: Foundation for Retrovirology and Human Health.
168. Sampson, M., Torres, R. A., Stein, A., Cochrane, J. M., Taylor, B., Mcintyre, K., Shay, W., Barr, M. R., & Fischer, L. (1997). Ritonavir-saquinavir combination treatment in protease inhibitor experienced patients with advanced HIV disease. In 37th ICAAC (p. 262), Toronto, Canada, September 28-October 1. Washington, D.C.: American Society of Microbiology.
169. Schapiro J.M., Winters M.A., Stewart F., Efron B., Norris J., Kozal M.J., Merigan T.C. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med. 124:1996;1039-1050.
170. Schapiro J.M., Lawrence J., Speck R., Winters M.A., Efron B., Coombs R.W., Collier A.C., Merigan T.C. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS Clinical Trials Group 229. J Infect Dis. 179:1999;249-253. a.
171. Schapiro J.M., Winters M.A., Lawrence J., Merigan T.C. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS. 13:1999;359-365. b.
172. Schmit J.C., Ruiz L., Clotet B., Raventos A., Tor J., Leonard J., Desmyter J., De C.E., Vandamme A.M. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS. 10:1996;995-999.
173. Schock H.B., Garsky V.M., Kuo L.C. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J Biol Chem. 271:1996;31957-31963.
174. 3. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infection (p. 206), Washington, D.C., January 22-26. Alexandria: Foundation for Retrovirology and Human Health.
175. Seelmeier S., Schmidt H., Turk V., von der Helm K. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc Natl Acad Sci USA. 85:1988;6612-6616.
176. Squires, K., Gulick, R., Santana, J., Powderly, W., Esinhart, J., Schoellkopf, N., & Stevens, M. (1998). An open-label, randomized, comparative study of d4T+ 3TC + IDV versus ZDV + 3TC + IDV in treatment naive HIV-infected patients. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infection (p. 150), Chicago, IL, February 1-5. Alexandria: Foundation for Retrovirology and Human Health.
177. Staszewski S., Morales-Ramirez J., Tashima K.T., Rachlis A., Skiest D., Stanford J., Stryker R., Johnson P., Labriola D.F., Farina D., Manion D.J., Ruiz N.M. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 341:1999;1865-1872.
178. St Clair M., Millard J., Rooney J., Tisdale M., Parry N., Sadler B.M., Blum M.R., Painter G. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res. 29:1996;53-56.
179. Steigbigel, R. T., Berry, P., Mellors, J., McMahon, D., Teppler, H., Stein, D., Drusano, G., Deutsch, P., Yeh, K., Hildebrand, C., Nessly, M., Emini, E., & Chodakewitz, J. (1996). Efficacy and safety of the HIV protease inhibitor indinavir sulfate (MK 639) at escalating doses. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infection (p. 80), Washington, D.C., January 28-February 1. Arlington: Foundation for Retrovirology and Human Health.
180. Stein D.S., Fish D.G., Bilello J.A., Preston S.L., Martineau G.L., Drusano G.L. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS. 10:1996;485-492.
181. Stewart, K., Park, C., Nienaber, V., Sham, H., Betebenner, D., Chen, C., Wideburg, N., Saldivar, A., Kati, W., Rosenbrook, W., Flentge, C., Chen, X., Molla, A., Kempf, D., & Norbeck, D. (1997). Molecular modeling and x-ray crystallographic studies of ritonavir, ABT-378, and their analogs bound to HIV protease. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infection (p. 102), Washington, D.C., January 22-26. Alexandria: Foundation for Retrovirology and Human Health.
182. Swanstrom R., Wills J.W. Synthesis, assembly, and processing of viral proteins. Coffin J.M., Hughes S.H., Varmus H.E. Retroviruses. 1997;263-334 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
183. Tang J., James M.N., Hsu I.N., Jenkins J.A., Blundell T.L. Structural evidence for gene duplication in the evolution of the acid proteases. Nature. 271:1978;618-621.
184. Tebas P., Patick A.K., Kane E.M., Klebert M.K., Simpson J.H., Erice A., Powderly W.G., Henry K. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS. 13:1999;F23-F28.
185. Teppler, H., Pomerantz, R., Bjornsson, T., Pientka, J., Osborne, B., Woolf, E., Yeh, K., Deutsch, P., Emini, E., Squires, K., Saag, M., & Waldman, S. (1993). Pharmacokinetics and tolerability studies of L-735,524, a new HIV protease inhibitor. In Abstracts of the 1st National Conference on Human Retroviruses Related Infection (abstract L8), Washington, D.C., January 29-February 2. Arlington: Infectious Disease Society of America.
186. Thompson, M. (1998). Activity of soft gelatin capsule formulation of saquinavir in combination with two nucleosides in treatment-naive HIV-1-seropositive persons. In Abstracts of the 12th World AIDS Conference (p. 40), Geneva, Switzerland, June 28. Stockholm: International AIDS Society.
187. Tisdale M., Myers R.E., Maschera B., Parry N.R., Oliver N.M., Blair E.D. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother. 39:1995;1704-1710.
188. Toh H., Kikuno R., Hayashida H., Miyata T., Kugimiya W., Inouye S., Yuki S., Saigo K. Close structural resemblance between putative polymerase of a Drosophila transposable genetic element 17.6 and pol gene product of Moloney murine leukaemia virus. EMBO J. 4:1985;1267-1272.
189. Vacca J.P., Dorsey B.D., Schleif W.A., Levin R.B., McDaniel S.L., Darke P.L., Zugay J., Quintero J.C., Blahy O.M., Roth E., Sardana V.V., Schlabach A.J., Graham P.I., Condra J.H., Gotlib L., Holloway M.K., Lin J., Chen I.-W., Vastag K., Ostovic D., Anderson P.S., Emini E.A., Huff J.R. L-735,524. an orally bioavailable human immunodeficiency virus type 1 protease inhibitor Proc Natl Acad Sci USA. 91:1994;4096-4100.
190. Vaillancourt M., Irlbeck D., Smith T., Coombs R.W., Swanstrom R. The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance. AIDS Res Hum Retroviruses. 15:1999;355-363.
191. Vogt V.M., Eisenman R. Identification of a large polypeptide precursor of avian oncornavirus proteins. Proc Natl Acad Sci USA. 70:1973;1734-1738.
192. Vogt V.M., Eisenman R., Diggelmann H. Generation of avian myeloblastosis virus structural proteins by proteolytic cleavage of a precursor polypeptide. J Mol Biol. 96:1975;471-493.
193. Vogt V.M., Wight A., Eisenman R. In vitro cleavage of avian retrovirus Gag proteins by viral protease p15. Virology. 98:1979;154-167.
194. von der Helm K. Cleavage of Rous sarcoma viral polypeptide precursor into internal structural proteins in vitro involves viral protein p15. Proc Natl Acad Sci USA. 74:1977;911-915.
195. Wei X., Ghosh S.K., Taylor M.E., Johnson V.A., Emini E.A., Deutsch P., Lifson J.D., Bonhoeffer S., Nowak M.A., Hahn B.H., Saag M.S., Shaw G.M. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:1995;117-122.
196. Wilson S.I., Lowri H.P., Mills J.S., Gulnik S.V., Erickson J.W., Dunn B.M., Kay J. Escape mutants of HIV-1 proteinase. enzymic efficiency and susceptibility to inhibition Biochim Biophys Acta. 1339:1997;113-125.
197. Winters M.A., Schapito J.M., Lawrence J., Merigan T.C. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol. 72:1998;5303-5306.
198. Wlodawer A., Erickson J.W. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem. 62:1993;543-585.
199. Wlodawer A., Miller M., Jaskolski M., Sathyanarayana B.K., Baldwin E., Weber I.T., Selk L.M., Clawson L., Schneider J., Kent S.B. Conserved folding in retroviral proteases. crystal structure of a synthetic HIV-1 protease Science. 245:1989;616-621.
200. Wong J.K., Hezareh M., Gunthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1997;1291-1295.
201. Workman, C., Musson, R., Dyer, W., & Sullivan, J. (1998). Novel double protease combinations-combining indinavir (IDV) with ritonavir (RTV): results from first study. In Abstracts of the 12th World AIDS Conference (p. 338), Geneva, Switzerland, June 28. Stockholm: International AIDS Society.
202. Xie D., Gulnik S., Gustchina E., Yu B., Shao W., Qoronfleh W., Nathan A., Erickson J.W. Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pH. Protein Sci. 8:1999;1702-1707.
203. Yoshinaka Y., Luftig R.B. Partial characterization of a P70 proteolytic factor that is present in purified virions of Rauscher leukemia virus (RLV). Biochem Biophys Res Commun. 76:1977;54-63.
204. Zennou V., Mammano F., Paulous S., Mathez D., Clavel F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol. 72:1998;3300-3306.
205. Zhang Y.-M., Imamichi H., Imamichi T., Lane H.C., Falloon J., Vasudevachari M.B., Salzman N.P. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol. 71:1997;6662-6670.
206. Zolopa, A. R., Hertogs, K., Shafer, R., Dehertogh, P., De Vroey, V., Efron, B., Bloor, S., & Larder, B. (1999) A comparison of phenotypic, genotypic and clinical/treatment history predictors of virological response to saquinavir/ritonavir salvage therapy in a clinic-based cohort. In Abstracts of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies (p. 47), San Diego, CA, June 23-26. London: International Medical Press, Ltd.